Neonmind’s NEO-002 synthetic psilocybin candidate will be studied like a lower-dose procedure to manage and suppress patient appetite. The company has secured pharmaceutical grade synthetic psilocybin from Psygen and anticipates initiating a Stage I/II proof-of-principle review for NEO-001 from the close to future. Simpson was billed with manufacturing the https://emilep665aoc0.nizarblog.com/profile